Content Hub

The 4th Cell Therapy for Autoimmune Disease Summit brings together the companies, researchers, and clinical leaders working to define the future of immune reset therapies. As autoimmune cell therapy moves beyond early proof-of-concept studies and into a new phase of clinical maturity, the industry's focus is shifting toward durability, safety, patient selection, manufacturing readiness, and commercialization.

Explore the articles below to gain insight into the latest developments across CAR-T, CAR-NK, Treg, MSC, allogeneic, autologous, and in vivo cell therapy approaches, alongside the practical challenges shaping the field. From immune reset and biomarker development to novel targets, scalability, reimbursement, and global development strategies, these discussions are helping determine how autoimmune cell therapies can evolve from promising clinical programs into broadly accessible treatments for patients.